Liposomal Annamycin Shows Synergistic Activity Against Leukemia, Lymphoma, Breast, Lung, and Colon Cancers in Preclinical Models When Combined with Chemotherapies

Liposomal annamycin, when combined with several FDA-approved chemotherapies, shows synergistic activity against a range of hematologic and solid tumors in preclinical models. The research indicates that this combination may offer a potential strategy for treating resistant and high-risk cancers. Preclinical studies revealed that liposomal annamycin, when used in conjunction with existing chemotherapeutic drugs, demonstrated broad synergistic effects across various cancer types. These included both hematologic cancers, such as leukemia and lymphoma, and solid tumors, which encompass cancers of the breast, lung, and colon, among others. Researchers observed the synergistic activity in laboratory models, suggesting a potentially more effective approach to combatting cancers that are resistant to current treatments, or that pose a high risk of recurrence. The data also suggests that this combination therapy could potentially be a safer therapeutic strategy.

Newsflash | Powered by GeneOnline AI
Date: May 1, 2025

Related posts:

Health Care Industry Faces Crisis as Patients Demand Accountability from Health Plans Drug Channels Institute Spotlights Amazon Pharmacy’s Retail Presence, Express Scripts’ Drug Trend Report Revival 4DMT’s 4D-150 Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Pharmacists Can Help Identify RSV Vaccine Candidates Among High-Risk Populations

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後